HR Execs on the Move

Syros

www.syros.com

 
Syros Pharmaceuticals is pioneering the understanding of the non-coding region of the genome to advance a new wave of medicines that control expression of disease-driving genes. Syros has built a proprietary platform that is designed to systematically and efficiently analyze this unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations. Because gene expression is fundamental to the function of all cells, the Company’s gene control platform has broad potential to achieve profound and durable benefit across a range of diseases. Syros is focused on cancer and immune-mediated diseases and ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.syros.com
  • 620 Memorial Drive Suite 300
    Cambridge, MA USA 02139
  • Phone: 617.744.1340

Executives

Name Title Contact Details
Conley Chee
 Chief Commercial Officer Profile
Jaimie Mailander
 Associate Director, Human Resources Profile
Harriet Winter
 Vice President, Global Product Leadership Profile
Jason Haas
 Chief Financial Officer Profile
Lisa Roberts
 Director Human Resources Profile

Similar Companies

Abner Labs

Abner Innovation Laboratories Limited (“Abner Labs”) is a British Columbia, Canada, company formed to acquire Abner Technology Group Limited (“Abner Group”), owner of the ibetmobile sports viewing and betting technology platform. This proprietary, artificial intelligence (“AI”) driven smart technology makes watching and wagering on live sports on any online device as easy as playing video games.

Helix Medical Communication

Helix Medical Communication is a Bridgewater, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

VativoRx

Celera Corporation

Celera Corporation (Celera) is a healthcare business delivering personalized disease management through a combination of products and services. The Company operates in three segments: a clinical laboratory testing service business (Lab Services), a

Emendo Biotherapeutics

Emendo biotherapeutics develops next generation gene editing tools for genetic disorders, addressing the current technological gaps for realizing the promise of gene therapy.